(Q33841597)

29 July 2017

1 reference

title

Recent advances in the therapy and prevention of CMV infections (English)

1 reference

29 July 2017

1 reference

Nichols WG

1 reference

29 July 2017

Boeckh M

series ordinal

1 reference

29 July 2017

publication date

1 February 2000

1 reference

Journal of Clinical Virology

29 July 2017

published in

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

25-40

1 reference

Polymerase chain reaction to detect cytomegalovirus DNA in the cerebrospinal fluid of neonates with congenital infection

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Severe cytomegalovirus infection in immunocompetent patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

The dynamics of human cytomegalovirus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infecti

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

1 reference

7 January 2021

Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Late-acute renal allograft rejection and symptomless cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

PCR activity of CMV in healthy CMV-seropositive individuals: does latency need redefinition?

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2899%2900065-7

7 January 2021

10.1016/S1386-6532(99)00065-7

Identifiers

DOI

1 reference

29 July 2017

1 reference